Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

Pitch Video

Investor Panel

corvidane.com

New York NY

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.

Corvidane raised $360k from over 200 Investors in previous RegCF.

Corvidane granted ~$700k in non-dilutive grants for Research and Development.

Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.

Corvida™ is protected by patents in the US, Japan and Brazil and are owned by the company.

Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.

Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.

This is an opportunity to impact global health and potentially realize significant financial gains.